- Home
- NMRA vs JRVR Comparison
NMRA vs JRVR Comparison
Compare NMRA & JRVR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NMRA
- JRVR
- Stock Information
- Founded
- NMRA 2019
- JRVR 2002
- Country
- NMRA United States
- JRVR Bermuda
- Employees
- NMRA N/A
- JRVR N/A
- Industry
- NMRA
- JRVR Property-Casualty Insurers
- Sector
- NMRA
- JRVR Finance
- Exchange
- NMRA Nasdaq
- JRVR Nasdaq
- Market Cap
- NMRA 268.5M
- JRVR 270.4M
- IPO Year
- NMRA 2023
- JRVR 2005
- Fundamental
- Price
- NMRA $1.57
- JRVR $5.37
- Analyst Decision
- NMRA Hold
- JRVR Buy
- Analyst Count
- NMRA 8
- JRVR 4
- Target Price
- NMRA $5.83
- JRVR $6.06
- AVG Volume (30 Days)
- NMRA 376.3K
- JRVR 313.8K
- Earning Date
- NMRA 11-11-2025
- JRVR 11-10-2025
- Dividend Yield
- NMRA N/A
- JRVR 0.75%
- EPS Growth
- NMRA N/A
- JRVR N/A
- EPS
- NMRA N/A
- JRVR N/A
- Revenue
- NMRA N/A
- JRVR $665,342,000.00
- Revenue This Year
- NMRA N/A
- JRVR $2.19
- Revenue Next Year
- NMRA N/A
- JRVR $7.93
- P/E Ratio
- NMRA N/A
- JRVR N/A
- Revenue Growth
- NMRA N/A
- JRVR N/A
- 52 Week Low
- NMRA $0.61
- JRVR $3.00
- 52 Week High
- NMRA $17.19
- JRVR $7.19
- Technical
- Relative Strength Index (RSI)
- NMRA 46.94
- JRVR 46.39
- Support Level
- NMRA $1.42
- JRVR $5.06
- Resistance Level
- NMRA $1.59
- JRVR $5.43
- Average True Range (ATR)
- NMRA 0.10
- JRVR 0.20
- MACD
- NMRA -0.03
- JRVR -0.03
- Stochastic Oscillator
- NMRA 36.14
- JRVR 46.27
About NMRA Neumora Therapeutics Inc.
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.
About JRVR James River Group Holdings Ltd.
James River Group Holdings Ltd owns and operates a group of specialty insurance and reinsurance companies. It reports business into three segments. The Excess and Surplus Lines segment, which is the key revenue driver, offers commercial excess and surplus lines liability and excess property insurance products; The Specialty Admitted Insurance segment focuses on niche classes within the standard insurance markets with a primary focus on fronting business, where it retains a minority share of the risk and seek to earn fee income by allowing other carriers and producers to use its licensure, ratings, expertise and infrastructure, and the Corporate and other segment consists of the management and treasury activities of holding companies, and equity compensation for the group.